MET and neoplasm: Some of these ADC targets are known oncoproteins, such as EGFR (targeted by two ADCs), HER-2, c-MET, Trop-2 or tumor antigens, such as tissue factor (CD142) and B7-H3, the latter being recently validated as a novel immune-checkpoint.